HannaH phase III randomised study: Association of total pathological complete response with event-free survival in HER2-positive early breast cancer treated with neoadjuvant–adjuvant trastuzumab after 2 years of treatment-free follow-up
European Journal of Cancer2016Vol. 62, pp. 62–75
Citations Over TimeTop 10% of 2016 papers
Christian Jackisch, Roberto Hegg, Daniil Stroyakovskiy, Jin‐Seok Ahn, Bohuslav Melichar, Shin‐Cheh Chen, Sung‐Bae Kim, Mikhail Lichinitser, Elżbieta Starosławska, Georg Kunz, S. Falcon, Shou‐Tung Chen, A. Crepelle-Fléchais, Dominik Heinzmann, Mona Shing, Xavier Pivot
Related Papers
- Docetaxel (Taxotere): preclinical and general clinical information.(1999)
- → The plinabulin/docetaxel combination to mitigate the known safety concerns of docetaxel.(2016)3 cited
- → Docetaxel (Taxotere) in the Treatment of Non-Small Cell Lung Cancer(2002)18 cited
- The effect of docetaxel combined with epirubicin on local advanced breast cancer(2011)
- TS-1 による術後補助療法中に発症しWeekly Docetaxel 療法により著効をみた胃癌腹膜播種の1 例(2005)